We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Figure 2.

Figure 2. From: Sirolimus Therapy to Halt the Progression of ADPKD.

Trend to increase the blood trough level of sirolimus despite mean dosage drug reduction during the 180 days of follow-up. (A and B) Daily sirolimus doses (A) and blood sirolimus trough levels (B) averaged over 30-day time intervals during the sirolimus treatment period in 15 patients with ADPKD. Data are means ± SE.

Norberto Perico, et al. J Am Soc Nephrol. 2010 June;21(6):1031-1040.
2.
Figure 1.

Figure 1. From: Sirolimus Therapy to Halt the Progression of ADPKD.

Renal volume changes during sirolimus and conventional treatment. (A) Absolute changes in TKV, TCV, and parenchymal and intermediate volumes during the two treatment periods in 15 patients with ADPKD. Kidney volumes are computed using a specifically designed volumetric quantification method based on Otsu's thresholding classification method. ○, Individual values; heavy lines, average values; thin lines, SEM. (B) Relative changes in TKV, TCV, and parenchymal and intermediate volumes during the two treatment periods in 15 patients with ADPKD. Relative changes are computed with respect to absolute volumes at the start of each treatment period. ○, Individual values; heavy lines, average values; thin lines, SEM.

Norberto Perico, et al. J Am Soc Nephrol. 2010 June;21(6):1031-1040.
3.
Figure 3.

Figure 3. From: Sirolimus Therapy to Halt the Progression of ADPKD.

ROC curve identifies the cutoff threshold of sirolimus dosage normalized to patient body weight that predicts treatment effect in reducing or reversing cyst volume growth. The vertical axis, sensitivity, represents the percentage probability that the reduction or reversal in cyst volume growth is detected by sirolimus dosage ratio higher than a given value. The horizontal axis, specificity, represents the percentage probability that sirolimus dosage ratio lower than a given value does not result in reduction or limitation in cyst volume growth. According to the ROC curve analysis, the highest accuracy in predicting treatment effect is at a threshold of 0.049 mg/kg sirolimus dosage to body weight ratio (sensitivity 75%, specificity 86%). The 45° dotted line indicates failure to identify a sirolimus dosage ratio that discriminates between effect and no effect of treatment. AUC, area under the curve for ROC.

Norberto Perico, et al. J Am Soc Nephrol. 2010 June;21(6):1031-1040.
4.
Figure 4.

Figure 4. From: Sirolimus Therapy to Halt the Progression of ADPKD.

Contrast-enhanced CT volumetric quantification technique and visualization of TCV changes. (A and B) CT image of a representative patient (A) and result of image analysis for the same slice (B), showing voxels classified as cysts (dark gray), parenchyma (white), and intermediate volume (light gray). Upper left corner insets show the regions enclosed by white boxes at high magnification. (C and D) Three-dimensional representation of the image data for the same patient (C) and the resulting volumetric quantification (D), showing the spatial distribution of renal cysts (translucent), intermediate volume (orange), and parenchyma (red). (E and F) Local changes in cyst volume occurring during sirolimus (E) and conventional treatment (F) for a representative patient, color-coded over the outer surface of the identified cyst volume (red for expansion, blue for shrinkage). Local changes are computed as the distance between the cyst volume surfaces at the start and end of the two treatment periods. TCV changes for the patient are −40.27 ml during sirolimus and 121.7 ml during conventional treatment.

Norberto Perico, et al. J Am Soc Nephrol. 2010 June;21(6):1031-1040.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk